Wedbush Issues Positive Outlook for Prime Medicine Earnings

Prime Medicine, Inc. (NYSE:PRME) – Equities researchers at Wedbush boosted their Q2 2025 earnings per share (EPS) estimates for Prime Medicine in a research report issued on Wednesday, July 16th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.40) per share for the quarter, up from their previous forecast of ($0.41). Wedbush has a “Outperform” rating and a $8.00 price target on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share. Wedbush also issued estimates for Prime Medicine’s Q3 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.39) EPS, FY2026 earnings at ($0.92) EPS, FY2027 earnings at ($0.81) EPS and FY2028 earnings at ($0.84) EPS.

Other analysts have also recently issued research reports about the stock. Chardan Capital lowered their price objective on shares of Prime Medicine from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. Citigroup reaffirmed a “neutral” rating and set a $1.50 price target (down previously from $10.00) on shares of Prime Medicine in a research note on Tuesday, May 27th. JMP Securities reduced their price objective on Prime Medicine from $10.00 to $6.00 and set a “market outperform” rating on the stock in a research report on Tuesday, May 20th. HC Wainwright cut Prime Medicine from a “buy” rating to a “neutral” rating in a report on Tuesday, May 20th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Prime Medicine in a research note on Tuesday, May 20th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Prime Medicine currently has a consensus rating of “Moderate Buy” and an average price target of $9.25.

Prime Medicine Trading Up 5.9%

PRME stock opened at $4.13 on Friday. The company’s 50 day moving average is $2.24 and its 200 day moving average is $2.22. The stock has a market cap of $555.47 million, a price-to-earnings ratio of -2.01 and a beta of 2.33. Prime Medicine has a 1-year low of $1.11 and a 1-year high of $5.95.

Institutional Investors Weigh In On Prime Medicine

Institutional investors and hedge funds have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. lifted its holdings in Prime Medicine by 4.2% in the first quarter. T. Rowe Price Investment Management Inc. now owns 4,143,096 shares of the company’s stock worth $8,245,000 after buying an additional 165,268 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Prime Medicine by 2.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,584,476 shares of the company’s stock worth $4,628,000 after acquiring an additional 38,515 shares during the period. Geode Capital Management LLC raised its position in shares of Prime Medicine by 7.9% in the 4th quarter. Geode Capital Management LLC now owns 1,467,606 shares of the company’s stock worth $4,287,000 after acquiring an additional 107,627 shares in the last quarter. Westwood Holdings Group Inc. lifted its stake in shares of Prime Medicine by 96.5% in the 4th quarter. Westwood Holdings Group Inc. now owns 883,129 shares of the company’s stock valued at $2,579,000 after purchasing an additional 433,653 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Prime Medicine by 3.9% in the 4th quarter. Northern Trust Corp now owns 544,937 shares of the company’s stock valued at $1,591,000 after purchasing an additional 20,389 shares during the period. 70.37% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, major shareholder David R. Liu acquired 21,000 shares of the firm’s stock in a transaction on Monday, June 23rd. The shares were purchased at an average price of $2.16 per share, for a total transaction of $45,360.00. Following the completion of the transaction, the insider owned 20,219,945 shares of the company’s stock, valued at $43,675,081.20. The trade was a 0.10% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have acquired 63,000 shares of company stock worth $110,250. Corporate insiders own 22.93% of the company’s stock.

About Prime Medicine

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.